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Abstract
Antiphospholipid syndrome is characterised by arterial and venous thromboembolic
events and pregnancy morbidity (mainly, recurrent foetal losses), in the presence of
antiphospholipid antibodies. Diagnosis is based on the presence of at least one laboratory
and at least one clinical manifestation of antiphospholipid syndrome. There are also so-
called “non-criteria” clinical features, and thrombocytopenia is one of the most important
among them. Thrombocytopenia has been reported with a prevalence between 30 and
46% among patients with antiphospholipid syndrome. The pathogenesis of thrombocyto-
penia related to antiphospholipid antibodies is not absolutely clear. Binding of antiphos-
pholipid antibodies to platelets and the promotion of platelet activation and aggregation
thus thrombus formation must be an important mechanism as well as the immune-medi-
ated clearance of platelets. Thrombocytopenia in antiphospholipid syndrome is usually
mild and does not require clinical intervention. The presence of thrombocytopenia in
patients with antiphospholipid syndrome is typically associated not with haemorrhagic
complications, rather it can trigger thrombotic events. Other causes of thrombocytopenia,
such as TTP, SLE,MDS, and ITP should be excluded. As thrombocytopenia is usually mild
and it predicts later thrombosis, patients may be given platelet aggregation inhibitors and/
or anticoagulant therapy. Anti-thrombotic treatment should be stopped only in case of
severe thrombocytopenia.
Keywords: antiphospholipid syndrome, APS, antiphospholipid antibody,
thrombocytopenia, thrombosis, SLE, pregnancy
1. About antiphospholipid syndrome
Antiphospholipid syndrome (APS) is characterised by arterial and venous thromboembolic events
and pregnancy morbidity (mainly, recurrent foetal losses), in the presence of antiphospholipid anti-
bodies (aPLs). APS (or Hughes’ syndrome) was first described by GR Hughes in 1983 [1]. APS is a
non-inflammatory autoimmune disease, or autoimmune thrombotic disorder, because autoantibodies
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are generated against different epitopes of the participant of the coagulation system (mainly
against phospholipid-binding proteins) that result in thrombosis. These antiphospholipid anti-
bodies are a heterogeneous group of autoantibodies. Lupus anticoagulant (LA), anti-cardiolipin
antibodies (ACA) and anti-β2 glycoprotein 1 (aβ2GPI) are the most important among them [2].
APS may be a secondary disease, as it frequently associates to systemic autoimmune diseases
such as SLE and also to malignant lymphoproliferative diseases and chronic hepatic disorders
[3]. On the contrary, APS can appear without any underlying disease, and in this case, it is
called primary antiphospholipid syndrome.
Neurologic involvement in APS is common and can be manifested by headaches, memory
impairment, dizziness, epilepsy and blurred vision, but the most common presentations are
transient ischaemic attacks and ischaemic strokes. Some of them are not thrombotic manifesta-
tions but are generated by connection of aPL antibodies and an antigen in the nervous system [4].
There is a special form of APS: the obstetric antiphospholipid syndrome (OAPS). It is
characterised clinically only by obstetrical morbidity: at least two unexplained miscarriages,
three non-consecutive miscarriages, preeclampsia, placental abruption, foetal growth restric-
tion, stillbirth, premature birth, or two or more unexplained in vitro fertilisation failures [5, 6].
Catastrophic antiphospholipid syndrome (CAPS) is rare, but very serious form of APS. The
mortality rate is very high. CAPS is characterised by thromboses generating in two or more
organs in a few days. That leads to infarction and necrosis of the affected tissues causingmultiple
organ failures [7].
Standard care for thrombotic APS is indefinite anticoagulation with a vitamin K antagonist [8].
There is currently insufficient evidence to recommend the routine use of direct oral anticoag-
ulants (DOAC) in thrombotic APS [9].
The 13th Task Force recommendation for primary thromboprophylaxis in APS supports the
use of aspirin [10]. A recent meta-analysis conducted on a total of 1208 asymptomatic patients
with persistently positive aPL has shown that low-dose aspirin (LDA) is associated with
significant risk reduction in arterial but not in venous thrombosis when compared to placebo
[11]. Aspirin with lowmolecular weight or unfractionated heparin may reduce the incidence of
pregnancy loss in obstetric APS [12]. Aspirin alone is advised for treating patients with aPL-
associated stroke or acute myocardial infarction [13].
Treatment regimens of APS further include hydroxychloroquine, statins, B-cell inhibitors,
complement inhibitors, blocking of aPL/B2 GPI receptors on target cells and tissue factor
inhibitors [14].
A combined therapy of anticoagulation, glucocorticoids, plasma exchange and intravenous
immunoglobulin (especially in the presence of infection) can be used in complicated cases of
multiorgan failure due to thrombosis as in CAPS. Cyclophosphamide can also be used in
CAPS in the presence of secondary autoimmune disease such as SLE [15]. Rituximab can also
be used in refractory cases after failure or inability to take the above-mentioned combined
therapies or in the presence of micro-angiopathic haemolytic anaemia [16].
However, the majority of aPL-positive patients do not have thrombosis. That is why the
stereotypical treatment for APS patients should be avoided and stratification of the thrombotic
Thrombocytopenia54
risks is important as aPLs are prevalently observed in various diseases or elderly population.
Current risk-stratification tools are largely limited to the antiphospholipid antibody profile
and traditional thrombotic risk factors.
Novel biomarkers that correlate with disease activity and potentially provide insight into
future clinical events include domain 1 specific anti-β2GPI antibodies, antibodies to other
phospholipids, or phospholipid-protein complexes (such as antiphosphatidylserine/prothrom-
bin antibodies (aPS/PT)), and functional/biological assays such as thrombin generation, com-
plement activation, levels of circulating microparticles, and annexin A5 resistance [17].
Clinical risk scores (antiphospholipid score (aPL-S) and the Global Anti-phospholipid Syn-
drome Score [GAPSS]) may also have value in predicting clinical events [18].
2. Diagnosis of APS
Diagnosis of APS is based on the Sapporo criteria (proposed in 1999 and updated in 2006 after
a conference in Sydney, Australia) [19].
These include at least one clinical and at least one laboratory manifestation of APS. Clinical
criteria include objectively confirmed venous, arterial, or small vessel thrombosis, and/or obstet-
ric morbidity including recurrent miscarriage, stillbirth, or intrauterine growth retardation.
The laboratory criteria require demonstration of a persistent presence of lupus anticoagulant
(LA), anti-cardiolipin (ACA) or anti-2GPI antibody (IgG or IgM). Antiphospholipid antibody
positivity can be stated if at least one of these antibodies could be detected twice, 12 weeks
apart. LA is measured by the help of coagulation tests, while ACA and anti-β2glycoprotein 1
(aβ2GPI) are determined by means of ELISA. LA results are expressed as qualitative data and
only strong positivity carries clinical significance. In case of ACA and aβ2GPI, antibody
medium/high titres of IgM and/or IgG subtype have important clinical value (Table 1).
Clinical symptoms of APS include thrombosis in any blood vessel of any organ. Typically,
thrombosis may recur and can present both in arteries and in veins. Anti-phospholipid anti-
bodies represent the strongest thrombophiliac factors, mainly LA.
Although thrombosis due to APS does not differ from thrombosis caused by any other factors,
some other symptoms and signs may accompany to the elevated blood clotting: for example, if
a patient presents with thrombosis and also has livedo reticularis, it is very likely that throm-
bosis is a manifestation of APS.
Besides, there are only a few situations when arterious and venous thrombosis present on the
same patient. This and the recurrence of the thrombotic event is very likely refers to APS.
There are the so-called “non-criteria” clinical features of APS, such as livedo reticularis, cardiac
valve disease, haematological manifestations (thrombocytopenia and haemolytic anaemia),
nephropathy and neurological manifestations (migraine, chorea and epilepsy).
Non-criteria manifestations mean that the presence of these characteristic features of the
disease is not a requisite of the diagnosis, or with other words, they are not the sine qua non of
the diagnosis.
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Thrombocytopenia is the most relevant non-criteria manifestation of APS.
However, despite the pro-thrombotic nature of APS, thrombocytopenia is one of the most
common non-criteria findings of the disease. Recently, thrombocytopenia is proposed to be a
diagnostic clinical criterion of APS.
In case of OAPS several disease processes may occur in the placentae of women with
antiphospholipid syndrome due to the antiphospholipid autoantibodies, not only thrombosis
and infarction, but also inflammatory events, mediated by cytokine release, complement
activation, angiogenic imbalance and activation of immune cells [20].
3. Epidemiology of APS
Presence of aPL Abs per se does not guarantee a patient will develop APS as only 8.1% of
patients with aPL antibodies without a history of clinical thrombosis developed thrombosis
during a 5-year follow-up period, suggesting that a patient needs an additional insult to
develop the clinical disease [21, 22]. The prevalence of the antibodies increases with age [23].
Forty percent of patients with APS have SLE. The prevalence of ACA in SLE is from 12 to 30%,
and LA is found in 5–34%. From the patients with SLE and aPL antibodies 50–70% progress to
APS.
The incidence of the APS is around five new cases per 100,000 persons per year, and the
prevalence is around 40–50 cases per 100,000 persons [24].
The aPLs are positive in approximately 13% of patients with stroke, 11% with myocardial
infarction, 9.5% of patients with deep vein thrombosis and 6% of patients with pregnancy
morbidity [16]. These data can underline the significance of APS.
Vascular
thrombosis
≥1 clinical episode of arterial, venous or small vessel thrombosis.
Thrombosis must be objectively confirmed.
For histopathological confirmation, thrombosis must be present without inflammation of the vessel
wall
Pregnancy
morbidity
≥1 unexplained death of a morphologically normal foetus ≥10 weeks of gestation
≥1 premature delivery of a morphologically normal foetus <34 weeks of gestation because of:
• severe preeclampsia or eclampsia defined according to standard definition;
• recognised features of placental insufficiency
≥3 unexplained consecutive miscarriages <10 weeks of gestation, with maternal and paternal factors
(anatomic, hormonal or chromosomal abnormalities) excluded
Laboratory
criteria
Presence of antiphospholipid antibodies (aPLs), on two or more occasions at least 12 weeks apart and
no more than 5 years prior to clinical manifestations, as demonstrated by ≥1 of the following:
• Lupus anticoagulant;
• Medium to high-titre (>40 GPL or MPL, or >99th percentile) anticardiolipin IgG or IgM;
• Anti-β2 glycoprotein-I (anti-β2GPI) IgG or IgM >99th percentile
Table 1. Revised classification criteria for antiphospholipid syndrome [19].
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According to another study, patients with cerebrovascular events who are less than 50 years
old have shown 17.4% prevalence of positive aPL with five times increase in the risk of
ischaemic stroke [25].
Thrombocytopenia is the most common non-criteria hematologic manifestation of APS. It has
been reported with prevalence between 30 and 46% among APS patients [26].
There is a difference between primary and secondary APS patients in respect of the frequency
of thrombocytopenia: in Euro-Phospholipid project, the frequency of thrombocytopenia in
patients with PAPS was 21%, while it was 41.9% in patients with secondary APS [27].
4. Role of platelets in APS
Platelets play a key role in APS-related thrombosis due to the presence of multiple receptors
that can interact with anti-β2-GPI antibodies (especially apolipoprotein E receptor 20 (apoER20)
and glycoprotein Ibα (GPIbα)) with consequent release of different pro-coagulant mediators
such as thromboxane B2, platelet factor 4 (PF4) and platelet factor 4 variant (CXCL4L1) [28].
In case of APS, thrombosis results from a hypercoagulable state caused by activation of
endothelial cells, monocytes and platelets. It has been demonstrated that platelets are required
for enhanced activation of the endothelium and fibrin generation by the anti-β2GP1 autoanti-
body/β2GP1 complex. Thus, the first event is the activation of thrombocytes, endothelial cells
are activated indirectly [29].
Platelet activation, a major contributing factor of arterial thrombosis in APS, might play a role
in APS-related thrombosis in at least two ways:
First, due to the presence of multiple receptors that can interact with antibodies, platelets can
facilitate the dimerisation of β2-GPI enhancing the coagulation response.
Second, platelets provide a surface for coagulation reactions [30].
The role of thrombocytes in the pathogenesis of APS is supported by the fact that circulating
platelet- and endothelial-derived microparticle level are elevated in patients with primary
APS [31].
Mouse models of APS have shown that platelets are the first target for circulating anti-β2-GPI-
β2-GPI complexes, and the enhancement of endothelium activation is also platelet thrombus-
dependent [29].
5. About thrombocytopenia in general
The normal value of platelet count is between 150 and 300  109/L. Platelet number between
100 and 150  109/L is considered as normal in some studies. That may be the cause of some
controversial research data. Decreased thrombocyte number might be present because of
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several reasons. The two main categories are the decreased thrombopoiesis in the bone mar-
row and the increased destruction of platelets in the peripheral blood [32].
Consequences depend on the degree of thrombocytopenia: under 20  109/L it is considered
severe, between 20 and 50  109/L moderate and above 50  109/L mild thrombocytopenia [33].
It is not only the number but also the thrombocyte function has a great importance in respect of
consequences of thrombocytopenia: even a few thrombocytes can provide a satisfactory per-
formance if the underlying disease does not diminish thrombocyte function. For example, in
case of acute leukaemia patient may have bleeding even with a higher platelet number than
that patient with immune thrombocytopenic purpura (ITP) who will be fine with a much
lower thrombocyte count.
In case of the so-called consumptive thrombocytopenia, the basic phenomenon is the activa-
tion of platelets. Activation leads to thrombosis generation, factors of blood coagulation such
as platelets are utilised and the thrombocyte number will decrease. As a secondary process
bleeding occurs (Table 2).
6. Thrombocytopenia in APS
Thrombocytopenia is frequently found in patients with the APS and is usually mild (70–
120  109/L) and benign, with no intervention required. In a few cases it can be severe and
aggressive treatment may be required. Low platelet counts usually appear associated with
other APS manifestations, but sometimes it may be the only sign of APS [35].
The same working group has compared the frequency of thrombocytopenia in different sub-
groups of APS. They found no differences in the occurrence of low platelet number in patients
with primary or secondary APS [35].
Thrombocytopenia is a frequent phenomenon of SLE. Increased concentrations of aPL anti-
bodies have been found to be common in patients not only with SLE, but also with immune
Increased platelet activation and destruction
Immune-mediated (aPL-related, secondary ITP)
Thrombotic microangiopathy (CAPS, HELLP syndrome, HUS, TTP)
Drug-induced (e.g., heparin)
Decreased platelet production
Haemophagocytic syndrome
Bone marrow necrosis
Increased platelet pooling
Pseudothrombocytopenia
CAPS: catastrophic antiphospholipid syndrome; HELLP: hemolysis, elevated liver enzymes, and low platelet count;
aHUS: atypical hemolytic uremic syndrome; TTP: thrombotic thrombocytopenic purpura.
Table 2. Mechanisms of thrombocytopenia in antiphospholipid antibody (aPL)-positive patients [34].
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thrombocytopenic purpura (ITP). No clinical significance or role in mechanisms of thrombo-
cytopenia of aPL antibodies was found [36]. In an earlier study, about 30% of ITP patients had
a positive aCL test at the time of diagnosis [37]. In case of Evans syndrome (thrombocytopenia
and haemolytic anaemia) aPL autoantibodies are also frequently present.
7. Pathogenesis of thrombocytopenia in APS
The pathogenesis of thrombocytopenia related to aPL antibodies is still unclear. It is possibly
caused by direct binding of anti-β2-GPI antibodies or anti-β2-GPI-β2-GPI complexes on acti-
vated platelets and promotes their aggregation and thrombus formation, so thrombocytopenia
is a consequence of consumption of platelets.
On the other hand, thrombocytopenia in APS may be due to immune-mediated clearance of
platelets, as in case of ITP [38].
8. Characterisation of thrombocytopenia in APS
Thrombocytopenia in APS is usually mild (70–120  109/L) and does not require clinical
intervention. In most of the cases, the main significance of thrombocytopenia is that it can be
a sign, and when noticed it, the presence of aPL antibodies can be found. Severe thrombocyto-
penia (platelet count <50  109/L) may be seen in 5–10% of patients [37].
9. Clinical significance of thrombocytopenia in APS
Interestingly, the presence of thrombocytopenia in patients with APS is not typically associated
with haemorrhagic complications; rather it can trigger thrombotic events. Even more, it has
been proven that the more severe the thrombocytopenia, the higher the probability of future
thrombosis.
In a retrospective study 138 patients were enrolled with positive aPL without fulfilling clinical
criteria for APS, after a mean follow-up of 146  60.3 months, 29.4% with thrombocytopenia
developed thrombosis. They concluded that aPL-positive patients who develop thrombocyto-
penia have a potential risk of developing thrombosis [39].
Platelet activation plays an essential role in the development of atherosclerosis. In case of
arterial thrombosis, the role of platelets is also essential. Continuous platelet activation in
patients with APS may be involved, among other factors, in accelerated atherosclerosis. More-
over, atherosclerosis and its thrombotic complications may be mediated by local secretion of
molecular effectors embedded or packed into microvesicles from the platelet surface [40].
A fundamental role of platelets and platelet activation in the process of thrombosis generation
of APS patients has been supported by several data. These data suggest that aPL antibodies do
not interact with circulating platelets in these patients. Instead, anti-β2-GPI-β2-GPI complexes
bind exclusively to the platelet thrombus and not to the endothelium, a phenomenon leading
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to the amplification of platelet activation [29]. A possible explanation might be that aCL
antibodies are able to bind the lipid component of platelet membrane only after platelet
activation. In fact, major binding targets are the anionic phospholipids phosphatidyl-serine
(PS), phosphatidylinositol (PI), and phosphatidyl-ethanolamine (PE), located in the inner sur-
face of the platelet lipid membrane that becomes exposed and accessible to anti-β2-GPI anti-
bodies after platelet activation.
10. Thrombocytopenia and risk stratification
Among aPL-positive patients, those with a low platelet count developed thrombosis more
frequently than those without. Among aPL-negative patients, no difference was found in the
predictive value of thrombosis regardless of platelet count [29].
11. Mean platelet volume (MPV) in APS
Beside thrombocytopenia, MCV alterations may have significant importance in APS. Though
conformation of data is still lacking, there are evidences that platelets with increased MPV are
more active than smaller platelets, with a greater pro-thrombotic potential because of higher
levels of intracellular TXA2 and an increased pro-coagulant surface [41]. MPV is largely
regarded as a useful surrogate marker of platelet activation [42].
MPV was found to be significantly higher in APS patients, especially in triple positive patients,
as compared to controls. Moreover, the level of MPV above 7.4 fl was found to be an indepen-
dent predictor of thrombosis recurrence in patients with APS [43].
12. Differential diagnosis of thrombocytopenia in APS
Pseudo-thrombocytopenia should be excluded. Presence of fragmentocytes can refer to TTP.
The observation of the characteristic “pentad” (fever, microangiopathic anaemia, thrombocy-
topenia, neurologic abnormalities and renal involvement) may strengthen the diagnosis.
Bone marrow examination can show out malignant haematological diseases such as multiple
myeloma, or different kind of leukaemia, when there is no place for normal thrombopoiesis.
In case of myelodysplastic syndrome (MDS), there are dysplastic features of the cells of
megakaryocytic cell line and also morphological abnormalities of thrombocytes can be
observed in the peripheral smear.
Haemolytic anaemia is indicative of secondary APS due to SLE, or Evans syndrome. Other-
wise, in case of SLE, not only haemolytic anaemia and thrombocytopenia may be found, but
also aPL antibodies, without any clinical symptoms of APS. Other clinical symptoms of the
systemic autoimmune disease or a history of thrombosis can help to differentiate, but it is not
always an easy task.
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Immune-thrombocytopenic purpura (ITP) is themost frequent cause of “megakaryocytic” throm-
bocytopenia. It is typically an exclusion diagnosis: when we cannot find any other reason of
decreased platelet number, and there are megakaryocytes in the bone marrow we consider ITP.
Thrombocytopenia is often experienced in pregnancy, affecting up to 10% of all pregnancies
[44]. The causes of pregnancy-specific thrombocytopenia are gestational thrombocytopenia,
pre-eclampsia, HELLP syndrome and acute fatty liver of pregnancy.
The most common cause of thrombocytopenia in pregnancy is gestational thrombocytopenia
(75% of all cases) [45]. It may be difficult to differentiate from ITP, which also presents frequently
during pregnancy, mainly in the first and second trimester. However, gestational thrombocyto-
penia generally causes mild thrombocytopenia, usually >70  109/L, from the mid-second or
third trimester, and is not related to adverse events for the mother and new-born. In some cases,
pregnancy might lead to worsening of thrombocytopenia in patients with ITP [46]. This may be
caused by the effects of the hormonal milieu of pregnancy on the reticuloendothelial system.
Thrombocytopenia is usually mild during pregnancy and is caused mainly by haemodilution.
However, ITP, or SLE, even APS can start during pregnancy. Therefore complete examination of
the patient, thorough laboratory checking, detailedmedical history and careful follow-up is crucial.
13. How to treat thrombocytopenia in APS?
The first task is to exclude concomitant SLE, or ITP, and ascertain whether thrombocytopenia
refers to an increased activation of the coagulation system or an elevated tendency of bleeding.
If it has been proven that thrombocytopenia is the manifestation of APS, it might have great
importance: it can predict later thrombosis.
As thrombocytopenia is usually mild and if it predicts later thrombosis, usually APS can be
treated by standard therapy. Patients can be given platelet aggregation inhibitors and/or
anticoagulant therapy. Anti-thrombotic treatment should be stopped only in case of severe
thrombocytopenia or bleeding [34].
In the presence of severe thrombocytopenia, rituximab represents a unique drug which can
balance the effect of bleeding and thrombosis. By reducing the production of autoantibodies,
rituximab can simultaneously raise the platelets and reduce the chance of thrombosis.
Rituximab can supersede splenectomy as a second-line therapy in this group of patients [47].
In case of SLE-associated APS, when severe thrombocytopenia is generated by disease activa-
tion SLE should be treated with high-dose glucocorticoids, IVIG, immunosuppressive agents
and plasma exchange [48, 49].
CAPS is a life-threatening disease that requires very aggressive treatment. The treatment strategy
is based on the combination of anticoagulation, glucocorticoids, plasma exchange and/or intra-
venous immunoglobulin, the so-called triple therapy. In refractory cases or in those with initial
life-threatening situation, rituximab may be an effective option [15]. Recently, some cases of
CAPS have been effectively treated with the addition of eculizumab to the triple therapy [50].
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In case of pregnancy-associated APS, the health of the mother is considered always the more
important. If there is a life-threatening situation, the pregnancy must be terminated. Pregnancy
itself represents a higher thrombotic risk, so careful anticoagulation is extremely important. On
the other hand, bleeding during delivery also should be avoided.
14. Conclusion
Thrombocytopenia may be a symptom of APS. Paradoxically, it refers to an elevated throm-
botic tendency, not bleeding risk. The causes of decreased platelet number are complex:
antiphospholipid antibodies that bind to platelets activate them and induce thrombosis.
Thrombocytes are consumed during this process. On the other hand, thrombocytopenia is the
consequence of destruction by immune mechanisms, like in the case of ITP. Sometimes, it
might be the only sign of APS.
Diagnosis is not easy; other causes of thrombocytopenia must be excluded by careful examinations.
Thrombocytopenia in APS is usually mild and per se does not require any treatment. Patients
with or without thrombocytopenia require anticoagulant medication in case of venous throm-
botic event while low-dose aspirin or clopidogrel is recommended after arterial thrombosis.
For OAPS, the combination of anticoagulant and thrombocyte aggregation inhibitor therapy is
advised. CAPS is a life-threatening disease with a rapid progression of multiorgan failure.
Even application of high-dose corticosteroids, plasma exchange, intravenous immunoglobulin
and complement inhibitor agent mortality is very high.
Abbreviations
APS antiphospholipid syndrome
aPL antiphospholipid antibody
aβ2GPI anti-β2 glycoprotein 1
ACA anti-cardiolipin antibody
CAPS catastrophic antiphospholipid syndrome
DOAC direct oral anticoagulants
ITP immune thrombocytopenic purpura
LA lupus anticoagulant
MDS myelodysplastic syndrome
OAPS obstetric antiphospholipid syndrome
SLE systemic lupus erythematodes
TTP thrombotic thrombocytopenic purpura
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